Skip to main content
Figure 5 | BMC Pharmacology and Toxicology

Figure 5

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Figure 5

Fasting plasma glucose concentration (FPG; mmol/L) – Change from baseline (pre- dose on Day 1 of each treatment period). MET BID, metformin 500 mg every 12 hours; RE BID, remogliflozin etabonate 500 mg every 12 hours; MET + RE BID, metformin 500 mg + remogliflozin etabonate 500 mg every 12 hours. Mean (and standard deviation) baseline FPG values for each treatment period: MET BID: 6.72 (1.88); RE BID, 6.98 (2.06); MET + RE BID, 6.42 (1.15).

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us